Ezra Cohen to Thyroid Neoplasms
This is a "connection" page, showing publications Ezra Cohen has written about Thyroid Neoplasms.
Connection Strength
4.132
-
An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. JCO Oncol Pract. 2024 Jul; 20(7):899-906.
Score: 0.607
-
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21(24):5420-6.
Score: 0.340
-
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 12; 74(6):1261-70.
Score: 0.317
-
A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases. Qual Life Res. 2015 Feb; 24(2):325-38.
Score: 0.313
-
The ACR appropriateness criteria® for thyroid carcinoma: searching for consensus in a rapidly evolving area. Oral Oncol. 2014 Jun; 50(6):575-6.
Score: 0.308
-
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 09 01; 120(17):2694-703.
Score: 0.308
-
Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther. 2012 Nov; 29(11):925-34.
Score: 0.276
-
New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6.
Score: 0.265
-
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr 01; 18(7):2056-65.
Score: 0.261
-
Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.
Score: 0.249
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13.
Score: 0.204
-
Iodine-refractory thyroid carcinoma. Rev Recent Clin Trials. 2006 May; 1(2):133-41.
Score: 0.176
-
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
Score: 0.143
-
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864.
Score: 0.090
-
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82.
Score: 0.089
-
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Lett. 2015 Apr 10; 359(2):269-74.
Score: 0.081
-
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46.
Score: 0.073
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.016
-
Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244. J Am Acad Dermatol. 2011 Feb; 64(2):e17-9.
Score: 0.015